Loading...
XKRX000250
Market cap2.37bUSD
Dec 23, Last price  
153,500.00KRW
1D
29.97%
1Q
9.49%
Jan 2017
1,211.97%
Name

Sam Chun Dang Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:000250 chart
P/E
—
P/S
17.82
EPS
—
Div Yield, %
0.03%
Shrs. gr., 5y
0.93%
Rev. gr., 5y
3.79%
Revenues
192.67b
+8.65%
76,650,143,370104,543,010,020118,924,047,670132,062,478,624147,372,999,944160,587,122,304159,960,312,377186,602,477,367166,862,333,786167,274,903,875177,335,410,013192,668,515,620
Net income
-10.38b
L
1,340,410,7608,723,680,83011,847,855,76011,628,174,5848,711,682,67812,514,554,5938,754,480,44210,451,684,443-965,677,310-16,555,159,1615,837,527,760-10,382,721,091
CFO
23.43b
+76.43%
1,602,316,28015,941,392,11019,549,843,90017,341,884,15017,763,757,17425,291,989,76123,614,470,69131,905,113,993610,383,330-7,214,503,43713,278,998,70023,428,068,360
Dividend
Dec 27, 201950 KRW/sh
Earnings
Jan 31, 2025

Profile

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. Its products include antibiotics, cures for the circulatory and respiratory system, medicines for the digestive system and ophthalmology, and anti-inflammatory. The company was founded on December 29, 1943 and is headquartered in Hwaseong-si, South Korea.
URL
http://www.scd.co.kr/
IPO date
Oct 04, 2000
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
192,668,516
8.65%
177,335,410
6.01%
167,274,904
0.25%
Cost of revenue
152,732,936
140,012,076
159,721,706
Unusual Expense (Income)
NOPBT
39,935,579
37,323,334
7,553,198
NOPBT Margin
20.73%
21.05%
4.52%
Operating Taxes
(271,038)
87,704
(9,188,213)
Tax Rate
0.23%
NOPAT
40,206,618
37,235,630
16,741,411
Net income
(10,382,721)
-277.86%
5,837,528
-135.26%
(16,555,159)
1,614.36%
Dividends
(880,822)
(968,353)
(968,353)
Dividend yield
0.05%
0.10%
0.10%
Proceeds from repurchase of equity
(99)
924,501
BB yield
0.00%
-0.10%
Debt
Debt current
33,696,014
4,085,459
22,293,299
Long-term debt
25,327,863
72,504,864
29,247,874
Deferred revenue
19,207,690
7,417,537
Other long-term liabilities
12,467,942
9,069,465
13,567,827
Net debt
(66,619,549)
(48,919,117)
(91,791,690)
Cash flow
Cash from operating activities
23,428,068
13,278,999
(7,214,503)
CAPEX
(6,765,881)
(46,545,924)
(29,306,657)
Cash from investing activities
(8,421,494)
(53,937,909)
(30,050,293)
Cash from financing activities
3,386,553
13,325,212
27,691,109
FCF
26,637,767
21,878,163
14,564,623
Balance
Cash
92,743,977
86,248,378
102,024,916
Long term investments
32,899,448
39,261,062
41,307,946
Excess cash
116,010,000
116,642,669
134,969,118
Stockholders' equity
197,595,031
197,134,302
202,164,408
Invested Capital
267,750,637
216,816,917
176,155,308
ROIC
16.59%
18.95%
10.29%
ROCE
10.41%
11.04%
2.43%
EV
Common stock shares outstanding
22,424
22,068
22,068
Price
77,300.00
76.48%
43,800.00
1.04%
43,350.00
-47.20%
Market cap
1,733,338,328
79.33%
966,580,196
1.04%
956,649,577
-46.22%
EV
1,744,680,211
989,561,784
941,063,702
EBITDA
48,366,013
44,974,205
14,293,751
EV/EBITDA
36.07
22.00
65.84
Interest
2,577,066
2,793,303
1,896,557
Interest/NOPBT
6.45%
7.48%
25.11%